BackgroundIn 2000, seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in the USA and resulted in dramatic reductions in invasive pneumococcal disease (IPD) and moderate increases in non-PCV7 type IPD. In 2010, PCV13 replaced PCV7 in the US immunisation schedule. We aimed to assess the effect of use of PCV13 in children on IPD in children and adults in the USA.MethodsWe used laboratory-based and population-based data on incidence of IPD from the Active Bacterial Core surveillance (part of the Centers for Disease Control and Prevention's Emerging Infections Program) in a time-series model to compare rates of IPD before and after the introduction of PCV13. Cases of IPD between July 1, 2004, and June 30, 2013, were classified as ...
Pneumococcal disease remains a global problem despite the availability of effective conjugate vaccin...
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
SummaryBackgroundThe 13-valent pneumococcal conjugate vaccine (PCV13) protects against key serotypes...
BACKGROUND: The 7-valent pneumococcal conjugate (PCV7) vaccine's impact on invasive pneumococcal dis...
Background The Streptococcus pneumoniae Invasive Disease network (SpIDnet) actively monitors popula...
BackgroundIn April 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 for use in...
Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization ...
Background. Changes in invasive pneumococcal disease (IPD) incidence were evaluated after 7 years of...
Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization ...
BackgroundA significant reduction in invasive pneumococcal disease (IPD) has been reported, across a...
BackgroundVaccine-serotype (VT) invasive pneumococcal disease (IPD) rates declined substantially fol...
Background. The impact of the 13-valent pneumococcal conjugate vaccine (PCV13) at the population lev...
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
Background. In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced a 7-valent vaccine ...
Rates of invasive pneumococcal disease have declined since widespread introduction of pneumococcal c...
Pneumococcal disease remains a global problem despite the availability of effective conjugate vaccin...
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
SummaryBackgroundThe 13-valent pneumococcal conjugate vaccine (PCV13) protects against key serotypes...
BACKGROUND: The 7-valent pneumococcal conjugate (PCV7) vaccine's impact on invasive pneumococcal dis...
Background The Streptococcus pneumoniae Invasive Disease network (SpIDnet) actively monitors popula...
BackgroundIn April 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 for use in...
Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization ...
Background. Changes in invasive pneumococcal disease (IPD) incidence were evaluated after 7 years of...
Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization ...
BackgroundA significant reduction in invasive pneumococcal disease (IPD) has been reported, across a...
BackgroundVaccine-serotype (VT) invasive pneumococcal disease (IPD) rates declined substantially fol...
Background. The impact of the 13-valent pneumococcal conjugate vaccine (PCV13) at the population lev...
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
Background. In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced a 7-valent vaccine ...
Rates of invasive pneumococcal disease have declined since widespread introduction of pneumococcal c...
Pneumococcal disease remains a global problem despite the availability of effective conjugate vaccin...
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
SummaryBackgroundThe 13-valent pneumococcal conjugate vaccine (PCV13) protects against key serotypes...